In this current study, we have identified and validated the protein expression of CD74 (and together with MIF) as providing survival information, and propose that CD74+ and MIF− together be considered to form a “signature” for stage IV melanoma prognosis, as we found on stage III melanoma [10]. Here, MIF is linked to melanoma.